certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
== Dye colour == The suffix "R" in the name of Coomassie brilliant blue R-250 is an abbreviation for "red" as the blue colour of the dye has a slight reddish tint. For the "G" variant the blue colour has a more greenish tint. The "250" originally denoted the purity of the dye. The colour of the two dyes depends on the acidity of the solution. The "G" form of the dye has been studied in detail. At a pH of less than 0 the dye has a red colour with an absorption maximum at a wavelength of 465 nm. At a pH of around 1 the dye is green with an absorption maximum at 620 nm while above pH 2 the dye is bright blue with a maximum at 595 nm. At pH 7 the dye has an extinction coefficient of 43,000 M−1 cm−1. The different colours are a result of the different charged states of the dye molecule. In the red form, all three nitrogen atoms carry a positive charge. The two sulfonic acid groups have extremely low pKa and will normally be negatively charged, thus at a pH of around zero the dye will be a cation with an overall charge of +1. The green colour corresponds to a form of the dye with no net overall charge. In neutral media (pH 7), only the nitrogen atom of the diphenylamine moiety carries a positive charge and the blue dye molecule is an anion with an overall charge of −1. The pKa values for the losses of the two protons are 1.15 and 1.82, respectively. The final proton is lost under alkaline conditions and the dye becomes pink (pKa 12.4). The dye interacts electrostatically but noncovalently with the amino and carboxyl groups of proteins.
==== Baldness can be caused by emotional stress and/or sleep deprivation ==== Emotional stress has been shown to accelerate baldness in genetically susceptible individuals. Stress due to sleep deprivation in military recruits lowered testosterone levels, but it is not noted to have affected SHBG. Thus, stress due to sleep deprivation in fit males is unlikely to elevate DHT, which is one cause of male pattern baldness. Whether sleep deprivation can cause hair loss by some other mechanism is not clear.
=== EC 1.99.2 Oxygenases (now covered by EC 1.13) === EC 1.99.2.1: deleted, now EC 1.13.11.12, lipoxygenase EC 1.99.2.2: deleted, now EC 1.13.11.1, catechol 1,2-dioxygenase EC 1.99.2.3: deleted, now EC 1.13.11.3, protocatechuate 3,4-dioxygenase EC 1.99.2.4: deleted, now EC 1.13.11.4, gentisate 1,2-dioxygenase EC 1.99.2.5: deleted, now EC 1.13.11.5, homogentisate 1,2-dioxygenase EC 1.99.2.6: deleted, now EC 1.13.99.1, inositol oxygenase
=== Vaccine skepticism and connection to autism === In 2009, Carrey wrote an article questioning the merits of vaccination and discussing its connection to autism for The Huffington Post. With former partner Jenny McCarthy, Carrey led a "Green Our Vaccines" march in Washington, D.C., to advocate for the removal of "toxic substances" from children's vaccines, out of a belief that children had received "too many vaccines, too soon, many of which are toxic". The rally was criticized by David Gorski, an American surgical oncologist on Science-Based Medicine blog, for being anti-vaccine and not "pro-safe vaccine", and by Steven Parker on the WebMD website for being "irresponsible". In 2009, the couple appeared on Larry King Live to discuss autism. Carrey stated that he believes autism "is preventable and treatable," and that "it's still shocking to see how many people are ignoring this information." Carrey suggested rising autism rates was a warning about the medical industry, stating: "There's an autistic child on every block ... Autism is the canary in the coal mine. I believe that it's telling us that this vaccine program is imbalanced." On July 1, 2015, after the signing of a new vaccination law, Carrey called California governor Jerry Brown a "corporate fascist" who was "poisoning" children by enacting the vaccination requirements. The law disallowed religious and philosophical reasons for exemption from vaccination.
Shaw's 2014 short film SMILF, which she wrote, directed and starred in opposite Thomas Middleditch, won the 2015 Short Film Jury Award for U.S. Fiction at Sundance. In 2015, SMILF was picked up by Showtime as a half-hour comedy television show with Shaw as showrunner, writing, directing, starring in, and producing the series. The first season, which was shot on location in South Boston as well as Los Angeles, received generally positive reviews, with her portrayal of single mother Bridgette Bird notable for its realism, insight, and biting humor. "Frankie Shaw, it [SMILF] marks the arrival of an important and original voice." SMILF co-stars Connie Britton and Rosie O'Donnell, and tackles subjects like eating disorders and sexual abuse. Shaw said that the show was a way to discuss and portray the role of women on screen. In November 2017, Showtime renewed SMILF for a second season. In December 2018, it was reported that Shaw and the series had been accused of workplace misconduct. In March 2019, the series was cancelled after two seasons. In 2016, Shaw returned to the Sundance Film Festival with another short film she wrote and directed, a dark comedy titled Too Legit, which stars Zoë Kravitz, Teresa Palmer, Nate Corddry and Clark Gregg. Too Legit is inspired by a satire of Congressman Todd Akin's controversial 2012 remarks about rape and pregnancy: "It seems to be, first of all, from what I understand from doctors, [rape resulting in pregnancy is] really rare.
Sources: en.wikipedia.org
Friendly-fire, which was previously enabled by default, was disabled in the retail version, bleeding - losing small amounts of health over time caused by injuries which "bled" - was removed, and a mini-map was added to more easily facilitate navigation and cooperation between fellow team members. UI improvements, including identifiers for differentiating team members from enemies and help messages that acted as a tutorial for new players, were also introduced in the retail release. At the end of July 2004, Valve shut down its WON authentication servers in favor of their digital distribution service Steam. All of Valve's games using the service were migrated to Steam, forcing players to use the new platform to access Day of Defeat. WON itself continued operating under Sierra/Activision until November 2008. In 2013, Valve released an update for Day of Defeat, alongside other GoldSrc games developed by Valve, which included versions of the game for Mac OS X and Linux.
Some molecular biology research suggests that GAHT induces a "unique molecular profile" with potential relevance to the recipient's immune system, or (in)susceptibility to certain health conditions (which are sometimes sexually dimorphic in people); one 2022 analysis found that GAHT (both feminizing and masculinizing) influenced gene expression. The study's lead author stated that they observed "changes [to] the epigenetic landscape of DNA" in some regions but not others, and that of the observed "epigenetic changes in regions of DNA that were distinct between sexes before hormone therapy, these regions consistently shifted towards the profile of the affirmed gender after 12 months of hormone therapy." A 2023 molecular study on the breast tissue of transgender men found that adding androgens induced such changes, appearing to silence genes across the breast tissue, including a suppression of genes linked to breast cancer.
Thus, the diocese was essentially divided into two parts, with the mainland patriarchate of Aquileia under the protection of the Lombards, and the insular patriarchate of Aquileia seated in Grado being protected by the exarchate of Ravenna and later the Doges of Venice, with the collusion of the Lombards. The line of the patriarchs elected in Aquileia would continue in schism until 699. However, although they kept the title of patriarch of Aquileia, they moved their residence first to Cormons and later to Cividale.
Sudan staining utilizes Sudan dyes to stain sudanophilic substances, often including lipids. Sudan III, Sudan IV, Oil Red O, Osmium tetroxide, and Sudan Black B are often used. Sudan staining is often used to determine the level of fecal fat in diagnosing steatorrhea.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.